Inflammasomes as biomarkers and therapeutic targets in traumatic brain injury and related-neurodegenerative diseases: A comprehensive overview
View/ Open
Publisher version (Check access options)
Check access options
Date
2023-01-31Author
Dania, KattanBarsa, Chloe
Mekhijian, Sarin
Shakkour, Zaynab
Jammoul, Maya
Doumit, Mark
Zabala, Maria Camila Pareja
Darwiche, Nadine
Eid, Ali H.
Mechref, Yehia
Wang, Kevin K.
de Rivero Vaccari, Juan Pablo
Munoz Pareja, Jennifer C.
Kobeissy, Firas
...show more authors ...show less authors
Metadata
Show full item recordAbstract
Given the ambiguity surrounding traumatic brain injury (TBI) pathophysiology and the lack of any Food and Drug Administration (FDA)-approved neurotherapeutic drugs, there is an increasing need to better understand the mechanisms of TBI. Recently, the roles of inflammasomes have been highlighted as both potential therapeutic targets and diagnostic markers in different neurodegenerative disorders. Indeed, inflammasome activation plays a pivotal function in the central nervous system (CNS) response to many neurological conditions, as well as to several neurodegenerative disorders, specifically, TBI. This comprehensive review summarizes and critically discusses the mechanisms that govern the activation and assembly of inflammasome complexes and the major methods used to study inflammasome activation in TBI and its implication for other neurodegenerative disorders. Also, we will review how inflammasome activation is critical in CNS homeostasis and pathogenesis, and how it can impact chronic TBI sequalae and increase the risk of developing neurodegenerative diseases. Additionally, we discuss the recent updates on inflammasome-related biomarkers and the potential to utilize inflammasomes as putative therapeutic targets that hold the potential to better diagnose and treat subjects with TBI.
Collections
- Medicine Research [1470 items ]